EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Nonclinical and Clinical Assessments of an Optimized Tablet Formulation of the Novel HER2-Selective Tyrosine Kinase Inhibitor Zongertinib: Focus on Relative Bioavailability and Impact of Variation of Gastric pH

Stefan Wölke, Behbood Sadrolhefazi iD, Habib Esmaeili, Sven Wind, Simone M Blattner iD, Guanfa Gan, Dongmei Qiang iD, Andrea Schirmer iD, Fabian Müller iD

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.5c00831 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Stefan Wölke und 8 weiteren Autor:innen. Beteiligte Einrichtung: Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Pyridines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Zongertinib (BI 1810631), a novel orally administered HER2-specific tyrosine kinase inhibitor, has recently received accelerated approval in the United States and China for patients with advanced, previously treated HER2 mutant NSCLC. This multifaceted analysis assessed the influence of gastric pH variation on the pharmacokinetics of conventional and spray-dried dispersion (SDD) formulations of zongertinib. The influence of gastric pH on zongertinib pharmacokinetics was evaluated in male beagles. Increased gastric pH substantially reduced absorption of zongertinib as a Natrosol suspension. At low gastric pH, the SDD formulation provided improved exposure and reduced variability compared with a conventional formulation. We then evaluated the in vitro release and bioaccessibility of conventional and SDD tablet formulations of zongertinib with the tiny-TIM gastrointestinal system. Bioaccessibility was similar between the two formulations under simulated fasted conditions; however, under simulated fasted conditions with a proton pump inhibitor, the conventional formulation showed reduced bioaccessibility versus SDD. In a randomized, open-label crossover study, fasted healthy human male participants received 30 mg zongertinib as a conventional tablet formulation, an SDD tablet formulation, and as an SDD tablet formulation after multiple doses of rabeprazole 40 mg. The primary pharmacokinetic end points were area under the plasma concentration-time curve from time 0 to the last quantifiable point (AUC0-tz) and maximum plasma concentration (Cmax) of zongertinib. Cmax and AUC0-tz were ∼39% and ∼35% higher, respectively, with the SDD versus the conventional formulation. Geometric mean Cmax and AUC0-tz were similar after treatment with zongertinib SDD with and without rabeprazole. Zongertinib SDD formulation showed good bioavailability irrespective of pH, supporting further clinical development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsPyridinesHumansMaleBiological AvailabilityAnimalsDogsTabletsCross-Over StudiesHydrogen-Ion ConcentrationAdultYoung AdultAdministration, OralDrug CompoundingTyrosine Kinase InhibitorsAnilidesQuinolines

Stichwörter der Autor:innen

HER2bioavailabilitypharmacokineticstyrosine kinase inhibitorzongertinib

Substanzen

TabletsProtein Kinase InhibitorsGSK 1363089PyridinesTyrosine Kinase InhibitorsAnilidesQuinolines

Autor:innen und Institutionen

  • Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany.
  • Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877-0368, United States.
  • Staburo GmbH, Aschauer Straße 26a, 81549 Munich, Germany.
  • Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Fahrstrasse 17, 91054 Erlangen, Germany.

ORCID-Profile: Behbood Sadrolhefazi, Simone M Blattner, Dongmei Qiang, Andrea Schirmer, Fabian Müller

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Wölke, S., Sadrolhefazi, B., Esmaeili, H., Wind, S., Blattner, S. M., Gan, G., Qiang, D., Schirmer, A., & Müller, F. (2025). Nonclinical and Clinical Assessments of an Optimized Tablet Formulation of the Novel HER2-Selective Tyrosine Kinase Inhibitor Zongertinib: Focus on Relative Bioavailability and Impact of Variation of Gastric pH. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00831

Vancouver

Wölke S, Sadrolhefazi B, Esmaeili H, Wind S, Blattner SM, Gan G, et al. Nonclinical and Clinical Assessments of an Optimized Tablet Formulation of the Novel HER2-Selective Tyrosine Kinase Inhibitor Zongertinib: Focus on Relative Bioavailability and Impact of Variation of Gastric pH. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00831

BibTeX
@article{Wlke2025,
  author = {Wölke, Stefan and Sadrolhefazi, Behbood and Esmaeili, Habib and Wind, Sven and Blattner, Simone M and Gan, Guanfa and Qiang, Dongmei and Schirmer, Andrea and Müller, Fabian},
  title = {Nonclinical and Clinical Assessments of an Optimized Tablet Formulation of the Novel HER2-Selective Tyrosine Kinase Inhibitor Zongertinib: Focus on Relative Bioavailability and Impact of Variation of Gastric pH},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.5c00831}
}
Kostenlos starten →